Authorization Systems for Use of Unlicensed Medicines in European Countries

Iryo To Shakai
doi 10.4091/iken.18.243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Health Care Science Institute

Related search

Unlicensed Medicines Use: A UK Guideline Analysis Using AGREE II

International Journal of Pharmacy Practice
EnvironmentalPublic HealthPharmacyHealth PolicyPharmaceutical ScienceMedicineOccupational Health
2018English

Rational Use of Medicines in Developing Countries

Journal of Pharmacy Practice and Research
PharmacologyPharmacy
2017English

The European Medicines Agency Facilitates Access to Medicines in Low- And Middle-Income Countries

Expert Review of Clinical Pharmacology
MedicineToxicologyPharmaceuticsPharmacology
2020English

Unlicensed Medicines in the UK – Legal Frameworks, Risks, and Their Management

Medicine Access @ Point of Care
2017English

Time to Entry for Cancer New Medicines: From European Union–wide Marketing Authorization to Patients Access in Belgium, Estonia, Scotland, and Sweden

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Why Urban Citizens in Developing Countries Use Traditional Medicines: The Case of Suriname

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2013English

Withdrawn Medicines Included in the Essential Medicines Lists of 136 Countries

PLoS ONE
Multidisciplinary
2019English

The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Do Rheumatoid Arthritis Patients Have Equal Access to Treatment With New Medicines? Tumour Necrosis Factor-Alpha Inhibitors Use in Four European Countries

Health Policy
Health Policy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy